Venus Remedies has received its first patent from US PTO for its novel research product, Vancoplus. With this patent grant, which is valid up to December 2027, the company is set to tap the US market by launching the product.
Vancoplus has already been granted the patents from countries like South Africa, New Zleand and Ukraine. Vancoplus, a brand of Ceftriaxone and Vancomycin along with the chemical vector, used in CVMC technology, is the only remedy after vaccination to treat MRSA and multi drug resistant microbes which causes Meningities, Pneumonia, Typhoid, Septicemia, Urinary Treat infection, skin and skin infections and staphylococcal Endocarditis, The drug restricts the production of toxin by MRSA pathogens and also reduces the treatment time, cost and adverse affects.
Vancoplus which took more than seven years after its development to receive the US patent is intended to be launched in early 2014 through 505(b)(2) route.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.20 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1230.90 |
| Zydus Lifesciences | 938.00 |
| Lupin | 2328.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: